Enanta Pharmaceuticals INC Form 4 insider transactions

Enanta Pharmaceuticals' Chief Product Strategy Officer, Tara Lynn Kieffer, was granted 81,000 stock options on November 27, 2024.

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, was granted 87,000 stock options on November 27, 2024.

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, was granted 87,000 stock options on November 27, 2024, exercisable over four years.

Enanta Pharmaceuticals' Chief Financial and Administrative Officer, Paul J. Mellett, was granted 81,000 stock options on November 27, 2024.

Enanta Pharmaceuticals' CEO, Jay R. Luly, was granted 250,000 stock options on November 27, 2024, which vest over four years.

Scott Rottinghaus, Chief Medical Officer of Enanta Pharmaceuticals, reports the forfeiture of shares to cover withholding taxes related to restricted stock unit settlements.

Chief Medical Officer Scott T. Rottinghaus of Enanta Pharmaceuticals executed multiple transactions involving the sale and exercise of common stock and stock options between July 11 and July 15, 2024.

Tara Lynn Kieffer, Chief Product Strategy Officer of Enanta Pharmaceuticals, sold 7,266 shares of common stock on June 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Matthew Paul Kowalsky, Chief Legal Officer of Enanta Pharmaceuticals, was granted stock options to purchase 150,000 shares of common stock.

Director Terry Vance acquired 15,700 stock options in Enanta Pharmaceuticals on March 6, 2024.

Director Lesley Russell acquired stock options for 15,700 shares of Enanta Pharmaceuticals on March 6, 2024.

Director Kristine Peterson acquired 15,700 stock options in Enanta Pharmaceuticals on March 6, 2024, exercisable over one year.

Director Yujiro S. Hata acquired stock options in Enanta Pharmaceuticals on March 6, 2024.

Mark G. Foletta, a director at Enanta Pharmaceuticals, acquired stock options exercisable for 15,700 shares of common stock on March 6, 2024.

Director Bruce L A Carter of Enanta Pharmaceuticals acquired stock options on March 6, 2024.

Nathaniel S. Gardiner, Chief Legal Officer of Enanta Pharmaceuticals, exercised stock options and acquired shares, while also reporting indirect ownership through a grantor retained annuity trust.